CARMAT Appoints Benoît de la Motte as CFO
May 26 2015 - 11:45AM
Business Wire
Regulatory News:
CARMAT (Paris:ALCAR) (FR0010907956, ALCAR, PEA-PME eligible),
the designer and developer of the world's most advanced total
artificial heart project, aiming to provide a therapeutic
alternative for people suffering from end-stage heart failure,
today announces the appointment of Mr Benoît de la Motte (49) as
CARMAT’s Chief Financial Officer.
Benoît de la Motte will be in charge of the Company’s
administrative and financial management, as well as investor
relations. Working in close collaboration with Senior Management,
he will contribute to the diversification of CARMAT’s financial
resources in line with the Company’s development.
“The internationally-recognized CARMAT project is symbolic of
France’s medical and technological innovation”, said Benoît de la
Motte, adding “I am delighted to be able to provide my financial
expertise of the industrial sector and contribute to the
development of this unique company.”
Benoît de la Motte has over 20 years of experience in Finance.
Before joining CARMAT, he was CFO at Nexeya, a company that
provides electronic solutions for the aerospace, defense, energy
and transport sectors. Since joining that listed company in 2008,
he has successfully led numerous development and integration
projects and accomplished various financial operations, including
some ten acquisitions and divestments as well as an LBO. From 2000
to 2007, Benoît was Financial Director Southern Europe at Diebold,
an American company listed on the NYSE and a global leader in the
ATM business for banks. From 1995 to 2000, he was Financial
Controller at Thales for its German operations. He began his career
as an Audit Manager at PWC.
Benoît de la Motte is a graduate of the EM Lyon business school
(1988), has an MBA from Pace University in New York (1988) and is a
chartered accountant (1997).
“We are pleased to welcome Benoît into our team. His experience
and his in-depth knowledge of industry and finance represent major
assets for CARMAT at a pivotal time in our development”, commented
Marcello Conviti, Chief Executive Officer of CARMAT.
●●●
About CARMAT: the world’s most advanced total artificial
heart project
A credible response to end-stage heart failure: CARMAT
aims to eventually provide a response to a major public health
issue associated with heart disease, the world’s leading cause of
death: chronic and acute heart failure. By pursuing the development
of its total artificial heart, CARMAT intends to overcome the
well-known shortfall in heart transplants for the tens of thousands
of people suffering from irreversible end-stage heart failure, the
most seriously affected of the 20 million patients with this
progressive disease in Europe and the United States.
The result of combining two types of unique expertise:
the medical expertise of Professor Carpentier, known throughout the
world for inventing Carpentier-Edwards® heart valves, which
are the most used in the world, and the technological expertise of
Airbus Group, world aerospace leader.
Imitating the natural heart: given its size, the choice
of structural materials and its innovative physiological functions,
CARMAT’s total artificial heart could, assuming the necessary
clinical trials are successful, potentially benefit the lives of
thousands of patients a year with no risk of rejection and with a
good quality of life.
A project leader acknowledged at a European level: with
the backing of the European Commission, CARMAT has been granted the
largest subsidy ever given to an SME by Bpifrance; a total of €33
million.
Strongly committed, prestigious founders and
shareholders: Airbus Group, Professor Alain Carpentier, the
Centre Chirurgical Marie Lannelongue, Truffle Capital, a leading
European venture capital firm, and the thousands of institutional
and individual shareholders who have placed their trust in
CARMAT.
For more information: www.carmatsa.com
●●●
Disclaimer
This press release and the information contained herein do not
constitute an offer to sell or subscribe to, or a solicitation of
an offer to buy or subscribe to, shares in CARMAT ("the Company")
in any country. This press release contains forward‐looking
statements that relate to the Company’s objectives. Such
forward‐looking statements are based solely on the current
expectations and assumptions of the Company’s management and
involve risk and uncertainties. Potential risks and uncertainties
include, without limitation, whether the Company will be successful
in implementing its strategies, whether there will be continued
growth in the relevant market and demand for the Company’s
products, new products or technological developments introduced by
competitors, and risks associated with managing growth. The
Company’s objectives as mentioned in this press release may not be
achieved for any of these reasons or due to other risks and
uncertainties.No guarantee can be given as to any of the events
anticipated by the forward-looking statements, which are subject to
inherent risks, including those described in the Document de
Référence filed with the Autorité des Marchés Financiers under
number D.15-0138 on March 16, 2015, changes in economic conditions,
the financial markets or the markets in which CARMAT operates. In
particular, no guarantee can be given concerning the Company’s
ability to finalize the development, validation and
industrialization of the prosthesis and the equipment required for
its use, to manufacture the prostheses, satisfy the requirements of
the ANSM, enroll patients, obtain satisfactory clinical results,
perform the clinical trials and tests required for CE marking and
to obtain the CE mark. CARMAT products are currently exclusively
used within the framework of clinical trials.
●●●
Name: CARMATISIN code:
FR0010907956Ticker: ALCAR
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150526005474/en/
CARMATMarcello ConvitiCEOPatrick
CoulombierCOOBenoît de la MotteCFOTel.: +33 (0)1 39 45
64 50contact@carmatsas.comorAlize RPPress
RelationsCaroline Carmagnol, Tel.: +33 (0)1 44 54 36
66carmat@alizerp.comorNewCapFinancial Communicationand
Investor RelationsDusan OresanskyEmmanuel HuynhTel.:
+33 (0)1 44 71 94 94carmat@newcap.fr
Carmat (EU:ALCAR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Carmat (EU:ALCAR)
Historical Stock Chart
From Apr 2023 to Apr 2024